Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of
bone tissue, leading to increased bone fragility that results in fractures. Pharmacological …

Introduction: Osteoporosis is a common skeletal disease with serious consequences due to
osteoporotic fractures and high costs to society for post-fracture care. Most patients at high …

Current osteoporosis medications reduce fractures significantly but have rare and serious
adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their …

Anabolic agents for the treatment of osteoporosis increase bone density, improve bone
strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their …

This review will summarize the evolving role of anabolic therapy in the management of the
postmenopausal woman at high risk for fracture. Pivotal clinical trial data for the three …

Therapy to activate bone formation is required to reverse and restore the damaged bone
architecture found in women with postmenopausal osteoporosis. The osteoanabolic drugs …

Osteoporosis is a common chronic condition that markedly increases the risk of fractures.
Osteoporotic-related fractures increase morbidity and mortality and impair quality of life …

Recent evidence confirms the superiority of osteoanabolic therapy compared to anti-
remodeling drugs for rapid improvement in bone density and fracture risk reduction …

Although several effective therapies are available for the treatment of osteoporosis in
postmenopausal women and older men, there remains a need for the development of even …

Introduction: Osteoporotic fracture is a cause of pain, loss of autonomy and excess mortality.
Current drugs however, do not allow for a satisfactory non vertebral fracture risk reduction …